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This article reviews the existing realities in Uganda to identify opportunities and potential obstacles of providing
universal routine HPV vaccination to young adolescent girls. Cervical cancer is a public health priority in Uganda
where it contributes to about 50–60% of all female malignancies. It is associated with a dismal 5-year relative
survival of approximately 20%. With adequate financial resources, primary prevention through vaccination is feasible
using existing education and health infrastructure. Cost-effectiveness studies show that at a cost of US$2 per dose,
the current vaccines would be cost effective. With optimal (≥70%) coverage of the target population, the lifetime
risk of cervical cancer could be reduced by >50%. Uganda fulfils 4 out of the 5 criteria set by the WHO for the
introduction of routine HPV vaccination to young adolescent girls. The existing political commitment, community
support for immunization and the favorable laws and policy environment all provide an opportunity that should
not be missed to introduce this much needed vaccine to the young adolescent girls. However, sustainable
financing by the government without external assistances remains a major obstacle. Also, the existing health
delivery systems would require strengthening to cope with the delivery of HPV vaccine to a population that is
normally not targeted for routine vaccination. Given the high incidence of cervical cancer and in the absence of a
national screening program, universal HPV vaccination of Ugandan adolescent girls is critical for cervical cancer
prevention.Introduction
Almost every case of cervical cancer is potentially prevent-
able. Yet, women in low- as opposed to those in high-
income settings have about a two fold cumulative risk of
developing cervical cancer before the age of 65 years [1].
Equally, women in low income settings have a threefold
risk of dying from cervical cancer than those in high in-
come settings [2]. Human papillomavirus is the primary
cause of cervical cancer (>99%) and is responsible for 83-
95% anal, 87% oro-pharyngeal, 60-65% vaginal and 20-
25% vulvar cancers in women [3]. A woman’s lifetime risk
of acquiring HPV infection is greater than 80% and most
infections occur within 3–4 years of sexual debut [4,5].
Among HIV positive women, the prevalence of HPV
infections and high grade cervical pre-cancer lesions (CIN
2/3) is several fold higher than in HIV negative women* Correspondence: cbanura@chdc.mak.ac.ug
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reproduction in any medium, provided the or[6,7]. Cervical cancer is the biggest single cause of years of
lost life particularly in low income settings where it affects
relatively young women at the peak of their productive
years [8].
Preventive HPV vaccines that protect against HPV 16
and 18 have been commercially available since 2006.
CervarixW made by GlaxoSmithKline (GSK) Biologicals,
Rixensart, Belgium and GardasilW made by Merck & Co.
Inc.,Whitestation, NJ, USA. The antigens in these vac-
cines protect against oncogenic HPV types 16 and 18 re-
sponsible for 70% of cervical cancers, globally [9]. The
remaining 30% of cervical cancer cases are caused by
other oncogenic HPV types. Results from recent studies
have shown some level of cross protection by both vac-
cines [10]. This implies that screening programs will still
be needed even after HPV vaccines are introduced.
Gardasil also prevents non oncogenic HPV 6 and 11 re-
sponsible for about 90% of genital warts but rarely cause
anogenital cancers [11].s is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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portunity to prevent approximately 70% of cervical can-
cer cases, globally [12]. Data from Sub Saharan Africa
however, seem to suggest that other oncogenic HPV
types are more prevalent and more diverse than else-
where in the world possibly because of prevalent HIV
infection [13,14]. This introduces uncertainty about the
proportion of cervical cancer cases that will be poten-
tially prevented by vaccination.
There is an urgent need for preventive HPV vaccines
in low-income settings particularly in Sub Saharan
Africa (SSA) given the elevated age standardized inci-
dence rates of cervical cancer [15]. However, the de-
mand for these vaccines so far is low. By the end of
2011, over 30 high- and middle- income settings had
introduced routine HPV vaccination in their national
vaccination programs compared to only one (Rwanda) in
SSA [16]. Past experience has shown that there is usually
a lag period of 15–20 years between the introduction of
new vaccines in high- and low- income settings due to
issues of financing, procurement and alternative path-
ways to vaccine development and production [17].
The World Health Organization (WHO) recom-
mends that routine HPV vaccination of young adoles-
cent girls could be integrated in national immunization
programs if 5 key criteria are fulfilled [18]. These in-
clude (i) Prevention of cervical cancer and other HPV
related-diseases, or both constitute a public health pri-
ority (ii) Vaccine introduction is programmatically feas-
ible (iii) Sustainable financing can be secured (iv) The
cost-effectiveness of vaccination strategies in the coun-
try or region is considered (v) HPV vaccination is tar-
geted to adolescent girls prior to sexual debut. This
article reviews the existing realities in Uganda to iden-
tify opportunities and potential obstacles of providing
universal routine HPV vaccination for young adolescent
girls.
Current realities
Prevention of cervical cancer and other HPV related-
diseases, or both constitute a public health priority in
Uganda
National data on cervical cancer burden in Uganda is not
available. However, based on data from the population-
based Kampala Cancer Registry (KCR), Uganda has one of
the highest cervical cancer incidence rates in the world
[19]. The age-standardized incidence rate per 100, 000 is
47.5, which is more than three times the global estimate
(15.8) [20]. Cervical cancer is the most frequently diag-
nosed cancer among women and the 2nd most frequent
cancer among women aged 15–44 years. It contributes to
about 40% of all malignancies reported by KCR, which
represent 50-60% of all female malignancies. Current esti-
mates show that annually, approximately 3500 women arenewly diagnosed and 2400 die from cervical cancer. Pro-
jections show that by 2025, about 6400 new cervical can-
cer cases and 4300 deaths will occur annually [20].
Since the 1960s, studies have shown an overall trend
of elevated cervical cancer incidence among Ugandan
women [21], which are probably an underestimate since
most women aged 15 years and older and at risk for cer-
vical cancer do not access health care. Not all health fa-
cilities are equipped to provide a full range of health
care services and referral services seldom work. There is
no organized national screening and treatment program.
The limited number of trained personnel, infrequent
supply of basic materials, poorly equipped laboratory
facilities and the potential difficulty of following-up
women with positive smears in a setting where there is
neither national identification cards nor street addresses
make it difficult to have an organized national screening
and treatment program [22].
Access to new proven and appropriate low cost screen-
ing technologies such as visual inspection with acetic acid
or Lugol’s Iodine (VIA/VILLI) that are based on “screen
and treat” of positive cases in a single visit are limited to
only a few referral health facilities. Similarly, the new
HPV-based screening technologies such as the careHPV™
test (Qiagen, Gaithersburg, MD, USA) presently under
evaluation at the national referral hospital is accessed by
very few women. Consequently, opportunistic cytology-
based screening is offered upon request in a few selected
hospitals.
The majority (72%) of cervical cancer patients seen at
the national referral hospital present with advanced dis-
ease [23]. Most of these women have never heard of cer-
vical cancer. Given the constraints posed by limited
resources in the public health sector, the availability of
care and treatment largely depend on the patient’s finan-
cial contribution. Home- based palliative care is limited
in geographical coverage [24]. Consequently, the prog-
nosis of cervical cancer patients is very poor with a 5-
year relative survival of approximately 20% compared to
about 64% for black Americans of USA [25].
Ugandan women are disproportionately affected by
HIV/AIDS accounting for 57% percent of approximately
1.2 million adults living with HIV [26]. Many studies in
Uganda have shown a higher prevalence and incidence
of oncogenic HPV infections among HIV positive than
HIV negative women [7]. Compared to HIV negative
women, HIV positive women seem to have higher risk
[27] and early onset of cervical cancer [28]. Although
HIV positive women seem to have a higher risk of dying
from cervical cancer, their 3-year relative survival is
similar to that of HIV negative women [29].
Other HPV-related cancers including anal, vulvar, va-
ginal and oro pharyngeal (excluding nasopharynx) are
rare in Ugandan women [20].
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The Uganda National Drug Authority registered both
HPV vaccines in 2007. Both were introduced in the pub-
lic sector through donations to the Ministry of Health
(MOH) [30,31]. GSK donated 50,000 doses of its bi-
valent vaccine (Cervarix) to vaccinate young girls in
Ibanda and Nakasongola districts [30]. A total of 417
primary schools and 69 health facilities in these districts
participated in the demonstration project [32]. A school-
based strategy was used in Ibanda district to vaccinate
all girls in primary 5. An age-based strategy was used in
Nakasongola district to vaccinate girls aged 10 years on
Child Days Plus (CDP); a program that targets all chil-
dren aged ≤14 years with an integrated package of pre-
ventive services including catch-up immunizations
[33,34]. Approximately 10,000 girls were fully vaccinated
over a three-year period. Coverage rates were higher in
Ibanda (>85%) than in Nakasongola (~50%) district pri-
marily because of the criteria used to select the girls for
vaccination [32].
Merck & Co., Inc. through the Gardasil Access Program
donated 1,600 doses of Gardasil to vaccinate 500 HIV
positive girls aged 9–15 years [31]. By the end of 2011,
about 200 young girls had received HPV vaccination [35].
Sustainable financing can be secured
The main sources of funding for the health sector in-
clude the central government, donor projects, global
initiatives and households through user fees levied in the
private wings of hospitals. Uganda is one of the world’s
poorest countries with approximately 38.0% of her
population living below the international poverty line
[36]. Compared to USA, Uganda’s expenditure as per-
centage of GDP is low, 16.2% and 8.2%, respectively [37].
Less than 10% of the total annual budget is allocated to
the health sector, which is far below the Abuja Declar-
ation target of 15% [38,39]. Uganda’s per capita expend-
iture on health estimated at only US$12.5 falls short of
the US$34 per capita recommended by the WHO for
delivery of a basic health care package that includes
immunization [40].
The cost-effectiveness of vaccination strategies in the
country or region is considered
Cost-effective analysis of HPV 16/18 vaccination in the
72 GAVI-eligible countries including Uganda has re-
cently been published [41]. Compared to no vaccination,
at a cost of US$2 per vaccine dose, which is equivalent
to International dollar (I$)10 per vaccinated adolescent
girl, HPV vaccination would be cost-effective in Uganda
(Table 1). Further, with optimal (≥70%) vaccine coverage
of a cohort of adolescent girls, the mean lifetime risk of
cervical cancer for Ugandan women could be reduced
by more than 50% [41].HPV vaccination is targeted to adolescent girls prior to
sexual debut
Uganda has one of the youngest populations in the
world with 50% of her population aged below 15 years
[42]. Although the median age of sexual debut for girls
is approximately 17.5 years, 11.1% of girls have initiated
sexual activity by the age of 15 years [43] A recent
multi-site survey showed that 8% of Ugandan girls aged
12–14 years reported having had sexual intercourse [44].
Another survey conducted in 24 districts of Uganda
showed that 6% girls aged 10–14 years reported a history
of sexually transmitted infections [45]. These studies
suggest the urgency of targeting young adolescent girls
prior to exposure to the virus.
Opportunities
Uganda has opportunities that could enhance the intro-
duction of universal routine HPV vaccination of young
adolescent girls including:
Political commitment
The GOU is committed to protecting women of child
bearing age from vaccine preventable diseases. In this re-
gard, the budget line for vaccines and related supplies is
protected in the MOH budget. Also, the ruling National
Resistance Movement party in its manifesto 2011–2016
pledged to scale up HPV vaccination [46].
Enabling laws and favourable policy environment
The Public Health Act 1935 (Ch 281) and 2000 revision
and the Local Government Act (Ch 243) [47,48]
mandate the GOU to purchase and introduce vaccines
for the public good. In the health sector, the current
policies on Health and Non Communicable Diseases
[49] provide a framework for strengthening health sys-
tems in order to improve access to primary prevention
measures. Such laws and policies would aid the intro-
duction and sustenance of universal routine HPV
vaccination program.
Vaccine acceptability
The ultimate success of universal routine HPV vaccin-
ation will partly depend on acceptability of the HPV
vaccine by the providers, parents and adolescents them-
selves. Although data on acceptability of the HPV vac-
cine is limited, health workers and teachers endorsed the
HPV vaccine [30]. Additionally, acceptability by parents
was high (80%) [30]. Parents were motivated to have
their daughters vaccinated by their positive perception
of the role of vaccines in disease prevention in general
and that HPV vaccination was a government program
[32]. The fact that approximately 10,000 girls completed
all the 3 doses of vaccination demonstrated their accept-
ability of the HPV vaccine [30]. The reasons for non
























Burundi 55.4 42.7 7,283 70 220 480
Kenya 55.4 28.7 18,047 60 320 770
Rwanda 55.4 49.4 8,786 c 130 370
Tanzania 50.7 68.6 50,110 50 160 340
Uganda 53.7 36.3 33,813 c 100 340
Source: Adopted from [41].
c Strategy cost effective compared to no vaccination.
ASR: Age standardized incidence rate.
DALYs: Disability Adjusted Life Years.
ICER: Incremental cost-effectiveness ratios.
I$: International Dollar.
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considerations e.g. school absenteeism on the day of vac-
cination rather than opposition to the vaccine [32].
Partnerships
From past experience, support from partners during the
initial phases of new vaccine introduction is critical.
GAVI has recently offered new support for HPV vaccine
[50]. Uganda has an opportunity to apply for the initial
funding support from GAVI and then assume the re-
sponsibility for financing gradually.
Creating synergies with existing programs
There is an opportunity to build synergies between HPV
vaccination and existing health programs such as the bi-
annual CDP program, which is widely accepted by the
community [34] and the school health program for Tet-
anus Toxoid (TT) vaccination [51].
HPV vaccination will bring together different stake-
holders including teachers, and health workers in the
departments of reproductive health, immunization, ado-
lescent health and cancer who normally do not work to-
gether. This provides an opportunity to pool together
available resources. With ample planning and appropri-
ate packaging of messages to the community, it is feas-
ible to deliver an HPV vaccine to young adolescent girls
using existing health and educational infrastructure if
adequate financial resources are available [30].
Potential obstacles
Cost
The cost of the vaccine and its delivery is still a major
potential obstacle. With Uganda’s high estimated popula-
tion growth rate of 3.6% per annum [52], the growth of
the immunization budget in real terms reduces signifi-
cantly. This means that any increase in funding
resources should be over and above the increase in theannual age cohort(s) targeted for HPV vaccination.
What’s more, is the volatile foreign exchange rate.
Should Uganda obtain GAVI funding support, issues of
co-financing and financing of the HPV vaccination pro-
gram beyond GAVI funding remains a major potential
obstacle [53]. Without compulsory health insurance and
with the low coverage of private health insurance,
Uganda has limited pooling of resources, and hence
minimal cross-subsidization [54]. In a recent study, the
cost of providing a single dose of HPV vaccine (exclud-
ing cost of vaccine) through a vertical school-based vac-
cination strategy was US$3.15 [30] comparable to the
cost of delivery (US$3.75) in Tanzania using the same
strategy [55]. Conversely, the cost of delivering a dose of
the HPV vaccine integrated into an existing outreach
program was estimated at US$1.65 [30]. Overall, ap-
proximately US$4 to US$10 per fully vaccinated girl
would be required for vaccine delivery costs.
Cultural barriers
Cultural barriers may arise for a vaccine targeting only
girls. From past experience, roumours that oral polio
and TT vaccines in Uganda were actually an anti-fertility
vaccines became widespread and were difficult to man-
age for some years [56]. Already, some few parents in
communities that participated in one of the HPV dem-
onstration projects were concerned about future fertility
of the vaccinated girls [32]. Such issues underscore the
importance of appropriate information and communica-
tion at all levels in the communities.
Operational and logistical challenges
Although school attendance of girls who participated in
the HPV demonstration project was high, attendance for
girls in upper primary classes (P5-7) in general is un-
acceptably low as a result of high dropout rates and
abseentism associated with menstruation [32,57]. In this
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ways of reaching girls who are absent on vaccination
days or those who are out of school [32]. Given the
widespread cultural practice of early marriages to older
and sexually experienced partners in most Ugandan
communities, out- of- school girls are the most vulner-
able to the acquisition of HPV infection. Emphasis
should be put on strategies such as integrating school-
based and outreach strategy on CDP so as to reach as
many adolescent girls with the HPV vaccine [30].
HPV vaccination will have an impact on the cold
chain, frequency of re-supply and transport at different
levels. With the existing infrastructure, the capacity to
store HPV vaccines seems inadequate as a result of
broken down equipment and shortage of gas cylinders
required to run the refrigerators during frequent power
outages [33]. Such challenges have been exacerbated by
increase in the number of districts from 50 in 2004 to
the current 112 where health infrastructure may be lim-
ited or nonexistent.
Introduction of routine HPV vaccination will bring to-
gether staff from the traditional infant and childhood
immunization, sexual and reproductive health and can-
cer control. These stakeholders will be involved in deci-
sion making on issues related to immunization. There
are currently on-going discussions within the MOH to
introduce pneumococcal, rotavirus and HPV vaccines
before 2015. These vaccines are more expensive than the
traditional infant and childhood vaccines [58]. At a
glance, it would seem reasonable to prioritize vaccines
against childhood infections because they are associated
with high mortality rates. However, preventing cervical
cancer would save the lives of relatively young women
who have critical roles in caring for children and their
families thus maintaining stability of households and
communities at large [59].
Education of policy makers and the general public about
HPV vaccines
Not all health policy makers are experts in the field of
cervical cancer prevention and therefore may not be
knowledgeable about HPV vaccines. Additionally, com-
munity members are generally uninformed about the
need for vaccination of adolescents. An additional chal-
lenge would be how to provide culturally appropriate
information to community members with limited or no
reading skills, and who may not have access to regular
mass media or may not even trust the government or
health authorities [60]. Therefore, it will be critical for
the MOH to involve local leaders in mobilization and
outreach activities [30] and in addition partner with
community- based public and private organization and
their networks for delivery of effective community
education.Conclusions
Uganda fulfils 4 out of the 5 criteria set by the WHO for
the introduction of routine HPV vaccination to young
adolescent girls. Given the high incidence of cervical
cancer and in the absence of a national screening pro-
gram, universal HPV vaccination of Ugandan adolescent
girls is critical for cervical cancer prevention.
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